J Gynecol Oncol.  2010 Mar;21(1):45-49. 10.3802/jgo.2010.21.1.45.

Endometrial carcinoma in vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic apoptosis assay: implications for endometrial cancer treatment

• Ballard KS
• Homesley H
• Hodson C
• Presant CA
• Rutledge J
• Hallquist
• Perree M

• KMID: 2173511
• DOI: http://doi.org/10.3802/jgo.2010.21.1.45

Abstract

OBJECTIVE
The in vitro microculture kinetic (MiCK) apoptosis assay has been used to predict single or combination chemotherapy response in leukemia patients. This feasibility study addressed MiCK in endometrial cancer specimens. METHODS: Endometrial cancer specimens from total abdominal hysterectomies were processed at a central laboratory. Single cell suspensions of viable endometrial cancer cells were plated in individual wells. Single and combination regimens were tested: combinations of doxorubicin, cisplatin, and paclitaxel and carboplatin and paclitaxel (Gynecologic Oncology Group [GOG] 209 endometrial cancer phase III trial arms) as well as single agent testing with paclitaxel, carboplatin, doxorubicin, cisplatin, ifosfamide, and vincristine (active agents in GOG trials). Apoptosis was measured continuously over 48 hours. RESULTS: Fifteen of nineteen patients had successful assays. The highest mean chemo sensitivity was noted in the combination of cisplatin, doxorubicin, and paclitaxel with lower mean chemosensitivity for carboplatin and paclitaxel. Combination chemotherapy had higher chemosensitivity than single drug chemotherapy. However, in 25% of patients a single drug had higher chemosensitivity than combination chemotherapy. As single agents, ifosfamide, cisplatin, and paclitaxel had the highest kinetic unit values. CONCLUSION: Using a panel of agents simulating clinical dose regimens, the MiCK assay was feasible in evaluating in vitro chemosensitivity of endometrial cancer. MiCK assay results correlated with GOG clinical trial results. However, 25% of patients might be best treated with single agent chemotherapy selected by MiCK. Ifosfamide, cisplatin, and paclitaxel appear to have high activity as single agents. MiCK may be useful in future new drug testing and individualizing endometrial cancer patient's chemotherapy management.

Keyword

Chemosensitivity assay; Chemotherapy; Endometrial cancer

MeSH Terms

Apoptosis
Carboplatin
Cisplatin
Doxorubicin
Drug Therapy, Combination
Endometrial Neoplasms
Feasibility Studies
Female
Humans
Hysterectomy
Ifosfamide
Leukemia
Paclitaxel
Suspensions
Vincristine
Carboplatin
Cisplatin
Doxorubicin
Ifosfamide
Paclitaxel
Suspensions
Vincristine

Reference

1. Kravtsov VD. A novel microculture kinetic assay (MiCK assay) for malignant cell growth and chemosensitivity. Eur J Cancer. 1994. 30A:1564–1570.

2. Kravtsov VD, Fabian I. Automated monitoring of apoptosis in suspension cell cultures. Lab Invest. 1996. 74:557–570.

3. Kravtsov VD, Greer JP, Whitlock JA, Koury MJ. Use of the microculture kinetic assay of apoptosis to determine chemosensitivities of leukemias. Blood. 1998. 92:968–980.

4. Kravtsov VD, Daniel TO, Koury MJ. Comparative analysis of different methodological approaches to the in vitro study of drug-induced apoptosis. Am J Pathol. 1999. 155:1327–1339.

5. Kravtsov VD, Priego V, Reilly GJ, Sethi H, Cooke J, Smith W, et al. Chemotherapy of myeloid leukemia directed by a microculture kinetic (MiCK) assay for apoptosis. 2000. In : The 42nd American Society of Hematology Meeting; Abstract 3129.

6. Kravtsov VD, Greer JP, Shyr Y, Haselton DJ, Whitlock JA, Goodman SA, et al. Prediction of survival and responses to chemotherapy in acute myelogeneous leukemia (AML) by the microculture kinetic (MiCK) assay of apoptosis. 1998. In : The 40th American Society of Hematology Meeting; Abstract 2790.

7. Kravtsov VD, Greer JP, Shyr Y, Whitlock JA, McCurley TL, Goodman SA, et al. Prediction of survival in acute non-lymphocytic leukemia. 2001. In : The 43rd American Society of Hematology Meeting; Abstract 4572.

8. Zhang J, Kravtsov V, Amarnath V, Picklo MJ, Graham DG, Montine TJ. Enhancement of dopaminergic neurotoxicity by the mercapturate of dopamine: relevance to Parkinson's disease. J Neurochem. 2000. 74:970–978.

9. Schultz R, Rothenberg M, Koury M, Hankins WD, Kravtsov V. Sequence dependence using combinations of Alimta™ (pemetrexed disodium, LY231514,MTA), gemcitabine, and oxaliplatin in human colorectal carcinoma cell lines. In : The 11th National Cancer Institute-European Organization for Research and Treatment of Cancer-American Association for Cancer Research Symposium; Abstract 503.

10. SAS. JMP, Version 7. Cary: SAS Institute Inc.;1989–2007.

11. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bull. 1945. 1:80–83.

12. Agresti A, Coull BA. Approximate is better than "exact" for interval estimation of binomial proportions. Am Stat. 1998. 52:119–126.

13. Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996. 62:278–281.

14. Broun GO, Blessing JA, Eddy GL, Adelson MD. A phase II trial of vincristine in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Am J Clin Oncol. 1993. 16:18–21.

15. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004. 22:2159–2166.

16. Lincoln S, Blessing JA, Lee RB, Rocereto TF. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003. 88:277–281.

17. Sutton GP, Blessing JA, DeMars LR, Moore D, Burke TW, Grendys EC. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Gynecol Oncol. 1996. 63:25–27.

18. Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004. 22:3902–3908.

19. Thigpen JT, Blessing JA, Homesley H, Creasman WT, Sutton G. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 1989. 33:68–70.

20. Presant CA, Bosserman L, Howard F, Emilio B. Patterns of metastatic (met) disease sites in breast cancer (BrCa): implications for availability of fresh tumor tissue (FTT) for personalized BrCa treatment (Rx) planning (Tp) in met disease. J Clin Oncol. 2009. 27:Suppl. abstr e12004.

21. Latimer RG, Presant CA, Hallquist AE, Perree M, Agapitos D. The value of personalized treatment (Rx) planning (PTP): cost savings (sav) by the microculture kinetic (MiCK) chemosensitivity (CS) assay, evidence from a large american self-insured company (ASIC). J Clin Oncol. 2009. 27:Suppl. abstr e17541.

22. Whitworth PW, Presant CA, Rutledge J, Hallquist A, Perree M, Agapitos D. Chemosensitivity (CS) of patient (pt) breast cancer (BrCa) cells in vitro: correlation with prior chemotherapy (CT) and implications for personalized treatment planning. J Clin Oncol. 2009. 27:Suppl. abstr e11563.